BMC cancer · 2025
Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seca Marta, Gronwald Jacek, Huzarski Tomasz, Glass Karen, Aeilts Amber, Kim Raymond H, Karlan Beth, Singer Christian F, Eisen Andrea, Tung Nadine, Olopade Olufunmilayo, Bordeleau Louise, Moller Pal, Foulkes William D, Neuhausen Susan L, Couch Fergus, Pal Tuya, Fruscio Robert, Cybulski Cezary, Lubinski Jan, Kim Shana, Sun Ping, Narod Steven A, Kotsopoulos Joanne, Hereditary Breast Cancer Clinical Study Group
Аннотация
BACKGROUND: The global trend toward delayed childbearing has led to an increased use of fertility treatment, including in vitro fertilization (IVF) and hormonal medications. Concerns regarding the potential impact of these interventions on breast cancer risk, particularly among high-risk women with a pathogenic variant in the BRCA1 or BRCA2 genes remains an important clinical concern.
METHODS: We conducted a matched case-control analysis of women carrying a pathogenic or likely pathogenic variant in BRCA1 or BRCA2 enrolled in a longitudinal, international study. The analysis included 4,145 women with invasive breast cancer (cases) and 4,145 matched controls without breast cancer. Data on infertility and use of fertility treatments was collected by a research questionnaire. Conditional logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for the association between infertility, fertility medications, and IVF, with the risk of breast cancer. Multivariable models were adjusted for parity and oral contraceptive use.
RESULTS: Among the 8,290 participants, 12% reported a history of infertility, 5% had used fertility medication, and 1% had undergone IVF. There was no statistically significant association between a history of infertility (OR = 0.96; 95% CI 0.84-1.10), use of any type of fertility medication (OR = 1.10; 95% CI 0.90-1.34), or IVF specifically (OR = 1.15; 95% CI 0.76-1.73) and the risk of BRCA-breast cancer. Findings were similar in the adjusted analyses.
CONCLUSIONS: Findings from this large, international study found no evidence for an association between infertility or fertility treatment and the risk of breast cancer among BRCA1 or BRCA2 carriers. Although based on low rates of exposure, these findings provide some reassurance to BRCA carriers considering fertility treatment. Future studies evaluating impact of contemporary protocols are needed.
METHODS: We conducted a matched case-control analysis of women carrying a pathogenic or likely pathogenic variant in BRCA1 or BRCA2 enrolled in a longitudinal, international study. The analysis included 4,145 women with invasive breast cancer (cases) and 4,145 matched controls without breast cancer. Data on infertility and use of fertility treatments was collected by a research questionnaire. Conditional logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for the association between infertility, fertility medications, and IVF, with the risk of breast cancer. Multivariable models were adjusted for parity and oral contraceptive use.
RESULTS: Among the 8,290 participants, 12% reported a history of infertility, 5% had used fertility medication, and 1% had undergone IVF. There was no statistically significant association between a history of infertility (OR = 0.96; 95% CI 0.84-1.10), use of any type of fertility medication (OR = 1.10; 95% CI 0.90-1.34), or IVF specifically (OR = 1.15; 95% CI 0.76-1.73) and the risk of BRCA-breast cancer. Findings were similar in the adjusted analyses.
CONCLUSIONS: Findings from this large, international study found no evidence for an association between infertility or fertility treatment and the risk of breast cancer among BRCA1 or BRCA2 carriers. Although based on low rates of exposure, these findings provide some reassurance to BRCA carriers considering fertility treatment. Future studies evaluating impact of contemporary protocols are needed.